This is a working overview of Regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-08. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Under mild reduction, the naturally occurred (-)-ptaquilosin 11 was obtained. The Yamada's synthesis proceeded in 20 steps with an overall yield of 2.9%. Similarly, the unnatural (+)-enantiomer of ptaquilosin was synthesized from the diastereomer of 2.
Shulman (1943), biophysicist, Sterling Professor emeritus at Yale University Seymour Jonathan Singer (1943), cell biologist and professor at the University of California, San Diego Enoch Callaway (1943), psychiatrist, professor at the University of California, San Francisco Arnold Cooper (1944), psychoanalyst; professor at Weill Cornell Medical College and former president of the American Psychoanalytic Association Robert Jastrow (1944), astronomer, founder of NASA's Goddard Institute for Space Studies and conservative think tank George C. Marshall Institute Joshua Lederberg (1944), winner of the Nobel Prize in Physiology or Medicine Arnold Scheibel (1944), professor of neuroscience at the University of California, Los Angeles Alfred P. Wolf (1944), nuclear and organic chemist; research professor at New York University Paul Marks (1945), geneticist, president emeritus of the Memorial Sloan Kettering Cancer Center, former editor-in-chief of the Journal of Clinical Investigation Jack Oliver (1945), professor of seismology at Columbia University and Cornell University Malvin Ruderman (1945), physicist known for discovering the RKKY interaction Leonard Shengold (1946), psychiatrist at New York University known for study on child abuse Albert Starr (1946), cardiovascular surgeon, winner of the 2007 Lasker Award Arthur Ashkin (1947), winner of the Nobel Prize in Physics in 2018 Robert A. Frosch (1947), fifth administrator of the National Aeronautics and Space Administration Norton Zinder (1947), scientist who discovered bacterial transduction Frank I.
==== Wound healing ==== Stem cells can also be used to stimulate the growth of human tissues. In an adult, wounded tissue is most often replaced by scar tissue, which is characterized in the skin by disorganized collagen structure, loss of hair follicles and irregular vascular structure. In the case of wounded fetal tissue, however, wounded tissue is replaced with normal tissue through the activity of stem cells. A possible method for tissue regeneration in adults is to place adult stem cell "seeds" inside a tissue bed "soil" in a wound bed and allow the stem cells to stimulate differentiation in the tissue bed cells. This method elicits a regenerative response more similar to fetal wound-healing than adult scar tissue formation. As of 2018, researchers were still investigating different aspects of the "soil" tissue that are conducive to regeneration. Because of the general healing capabilities of stem cells, they have gained interest for the treatment of cutaneous wounds, such as in skin cancer. Stem cell therapy has also been investigated for hair follicle regeneration. A clinical case report demonstrated improvement in hair loss following COVID-19 vaccination through combined administration of autologous CD34+ hematopoietic progenitor cell fraction and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs), with progressive recovery of hair density observed over 12 weeks of treatment without significant adverse effects.
=== Organizations === The World Health Organization Department of Food Safety and Zoonoses (FOS) provides scientific advice for organizations and the public on issues concerning the safety of food. Its mission is to lower the burden of foodborne disease, thereby strengthening the health security and sustainable development of Member States. Foodborne and waterborne diarrhoeal diseases kill an estimated 2.2 million people annually, most of whom are children. WHO works closely with the Food and Agriculture Organization of the United Nations (FAO) to address food safety issues along the entire food production chain—from production to consumption—using new methods of risk analysis. These methods provide efficient, science-based tools to improve food safety, thereby benefiting both public health and economic development.
Sources: en.wikipedia.org
Wellcome established its second corporate brand, First Choice, with a product range of over 1,000 items. With prices at 20–30% less than competitive international brands, it is a well-known brand in Hong Kong. A HK$400 million investment, "Wellcome Fresh Food Centre" was opened in 1998, occupying an area of 161,000 sq. ft. In the 1990s, Wellcome Hong Kong to become the first to use the UPC system in Hong Kong supermarkets, offers a more efficient and more convenient payment services. According to the report of 2004–2008, Wellcome supermarkets and thus increase the number of branches. Wellcome introduced the "Vote For Your Favourite Brand" campaign in 2000 and soon opened a superstore at Tuen Mun Town Plaza. The Wellcome superstore introduced a new "one-stop" shopping service, embracing the concepts of both wet market and grocery shop under one roof. Wellcome also began its double refund offer with lowest price guarantee by doubling the difference back to customers. Wellcome unveiled its Stanley store in January 2003. It is the first supermarket located inside a 100-year-old historical building – the old Stanley Police Station. In 2014, Wellcome Taiwan was found to have used contaminated ingredients in its mushroom and minced pork seasonings, drawing it into the 2014 Taiwan food scandal. Wellcome Taiwan was acquired by Carrefour in 2020. While Wellcome Philippines locations were turned into Robinsons Easymart after Robinsons Retail purchased Rustan's Supercenters.
D-amino-acid transaminase (EC 2.6.1.21) is an enzyme originally characterised from bacteria that catalyzes several reversible chemical reactions that interconvert specific D-amino acids and α-ketoglutaric acid with the corresponding α-keto acid and D-glutamic acid. For example, it can use D-alanine as a substrate:
== Effects == CJC-1295 may markedly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in animals and humans. With a single injection, in human subjects, CJC-1295 DAC may increase plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 0.5- to 3-fold for 9 to 11 days. With the inclusion of the DAC additive, the drug has an estimated half-life of about 6 to 8 days in humans. With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days. CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation. The extended half-life is achieved through the addition of a drug affinity complex (DAC) that binds to albumin, thus prolonging the peptide's presence in the bloodstream. It is primarily used for its potential to stimulate the release of growth hormone (GH) from the pituitary gland.
== Methods == Prohibited methods include manipulation of blood components (e.g. autologous red blood cell transfer, "blood doping"), manipulation of samples, and gene doping. These are prohibited at all times.
New fossil material of a colugo and ungulates, possibly including the first known upper dentition of Pakkokuhyus lahirii, is described from the Eocene Pondaung Formation (Myanmar) by Ducrocq et al. (2026). He et al. (2026) date the mammalian assemblage from the Relu Basin in the Tibetan Plateau (China) to 39.2–38.1 million years ago, and find that the presence of this assemblage in the studied area coincided with a seasonal rainfall regime, climatic conditions with similarities to Mediterranean-type climate, and expansion of high-elevation subtropical forests. Evidence of impact of both regional climate changes (mid-Eocene aridification of Central Asia) and global ones (Paleocene–Eocene thermal maximum and cooling during the Eocene-Oligocene transition) on changes of composition of Paleogene mammal assemblages from Central Asia is presented by Benevento et al. (2026). A study on the species richness and morphological diversity of mammals from assemblages from the John Day Formation (Oregon, United States) is published by Peng & Famoso (2026), who find evidence of stronger relationship of sampling at sites from the studied formation with recorded taxonomic diversity than with morphological diversity. Revision of the composition of the assemblages of Neogene terrestrial mammals from the Chesapeake Group (Maryland and Virginia, United States) is published by Eshelman et al. (2026), who interpret the studied faunas as indicative of presence of a combination of forest and grassland habitats, with a gradual shift towards more forested environments. Arias-Concha et al.
Sources: en.wikipedia.org
Disuse atrophy of muscles and bones, with loss of mass and strength, can occur after prolonged immobility, such as extended bedrest, or having a body part in a cast (living in darkness for the eye, bedridden for the legs etc.). This type of atrophy can usually be reversed with exercise unless severe. There are many diseases and conditions which cause atrophy of muscle mass. For example, diseases such as cancer and AIDS induce a body wasting syndrome called cachexia, which is notable for the severe muscle atrophy seen. Other syndromes or conditions which can induce skeletal muscle atrophy are congestive heart failure and liver disease. During aging, there is a gradual decrease in the ability to maintain skeletal muscle function and mass. This condition is called sarcopenia, and may be distinct from atrophy in its pathophysiology. While the exact cause of sarcopenia is unknown, it may be induced by a combination of a gradual failure in the satellite cells which help to regenerate skeletal muscle fibers, and a decrease in sensitivity to or the availability of critical secreted growth factors which are necessary to maintain muscle mass and satellite cell survival.
For an even-numbered saturated fat (Cn), 0.5 * n - 1 oxidations are necessary, and the final process yields an additional acetyl CoA. In addition, two equivalents of ATP are lost during the activation of the fatty acid. Therefore, the total ATP yield can be stated as:
=== Energy expenditure === The Na+/K+-ATPase is an active enzyme. It uses energy from ATP to move ions against their concentration gradient. In fact, all cells expend a large fraction of the ATP they produce (typically 30% and up to 70% in nerve cells) to maintain their required cytosolic Na and K concentrations. For neurons, the Na+/K+-ATPase can be responsible for up to three-fourths of the cell's energy expenditure. In many types of tissue, ATP consumption by the Na+/K+-ATPases have been related to glycolysis. This was first discovered in red blood cells (Schrier, 1966), but has later been evidenced in renal cells, smooth muscles surrounding the blood vessels, and cardiac cells which compose Purkinje fibers. Recently, glycolysis has also been shown to be of particular importance for Na+/K+-ATPase in skeletal muscles, where inhibition of glycogen breakdown (a substrate for glycolysis) leads to reduced Na+/K+-ATPase activity and lower force production.
The sale allows TGI Fridays to repay its $23.9 million bankruptcy loan, with about $8 million in cash left over. On January 29, 2025, it was announced TGI Fridays UK's flagship restaurant in Leicester Square, London, had closed down. On January 30, 2025, it was reported that 30 more locations had closed, which left the chain with only around 100 locations remaining in the US. On February 3, 2025, it was announced that 19 of TGI Fridays' corporate-owned restaurants had been sold to two separate franchisees: three to Sugarloaf Hospitality and 16 to Yadav Enterprises, and that TGI Fridays had rejected the leases for six more restaurants. On 31 October 2025, it was announced that Sugarloaf TGIF Management had acquired TGI Friday's 49 UK restaurants from Calveton UK and Breal Capital as part of an international consolidation of the brand under Ray Blanchette. Sugarloaf is establishing a UK-led management team for the restaurants. However, less than three months later, on 14 January 2026, TGI Fridays closed 16 restaurants and went into administration for the second time in a year.
== Interactions == Concurrent use with other triptans or ergot-containing medications (e.g., ergotamine, dihydroergotamine) within 24 hours can result in additive vasoconstriction. Increased systemic exposure to sumatriptan can occur if used within 2 weeks after a monoamine oxidase inhibitor (MAOI). Cases of serotonin syndrome have been reported with co-administration of triptans and serotonin reuptake inhibitors.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.